Statement on the potential inclusion of Nplate
(romiplostim) for future National Coverage
Determinations (NCDs).

Although American Autoimmune Related Diseases
Association (AARDA) does not take formal position
on the recommendation of any specific treatments,
we are very concerned that an NCD would affect
many patients by excluding or restricting
coverage of Nplate for Medicare and Medicaid
receipients, which may also influence other payer
coverage decisions. We strongly believe that
patients have the right to expect that their
medical decisions will be made by their own
medical providers. The inclusion of Nplate under
a NCD may impact usage, dosage, and timing which
ultimately would result in the elimination of
medical judgement on behalf of a medical
professional.